NovaBay Pharmaceuticals Files 8-K/A Amendment
Ticker: NBY · Form: 8-K/A · Filed: May 31, 2024 · CIK: 1389545
Sentiment: neutral
Topics: amendment, financial-reporting, exhibits
TL;DR
NovaBay amended its 8-K filing from March 25th, correcting/adding financial docs.
AI Summary
NovaBay Pharmaceuticals, Inc. filed an 8-K/A on May 31, 2024, to amend a previous filing regarding financial statements and exhibits. The original event date was March 25, 2024. The filing does not introduce new material events but serves to correct or supplement information previously submitted.
Why It Matters
This filing indicates a correction or addition to previously reported financial information, which could be important for investors to have the most accurate and complete data.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing, not a report of a new material event, suggesting it's for administrative or corrective purposes.
Key Players & Entities
- NovaBay Pharmaceuticals, Inc. (company) — Registrant
- May 31, 2024 (date) — Filing Date
- March 25, 2024 (date) — Original Event Date
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previous report, specifically to provide updated or corrected financial statements and exhibits.
What was the original date of the event being amended?
The original date of the event being amended was March 25, 2024.
When was this 8-K/A filing submitted to the SEC?
This 8-K/A filing was submitted to the SEC on May 31, 2024.
What specific items are being amended or supplemented in this filing?
The filing specifically mentions amendments related to 'Financial Statements and Exhibits'.
Does this filing report any new material events for NovaBay Pharmaceuticals?
No, this filing is an amendment (8-K/A) to a previous report and does not appear to report any new material events, but rather to correct or supplement existing information.
Filing Stats: 890 words · 4 min read · ~3 pages · Grade level 13.1 · Accepted 2024-05-31 16:43:25
Key Financial Figures
- $0.01 — h Registered Common Stock , par value $0.01 per share NBY NYSE American Check t
Filing Documents
- nby20240531_8ka.htm (8-K/A) — 32KB
- ex_682007.htm (EX-99.1) — 403KB
- 0001437749-24-018922.txt ( ) — 591KB
- nby-20240325.xsd (EX-101.SCH) — 3KB
- nby-20240325_def.xml (EX-101.DEF) — 12KB
- nby-20240325_lab.xml (EX-101.LAB) — 16KB
- nby-20240325_pre.xml (EX-101.PRE) — 12KB
- nby20240531_8ka_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (b) Pro Forma Financial Information The following unaudited pro forma financial information of the Company is filed as Exhibit 99.1 to this Current Report on Form 8-K: Unaudited Pro Forma Condensed Consolidated Balance Sheet as of March 31, 2024; Unaudited Pro Forma Condensed Consolidated Statement of Operations for the three months ended March 31, 2024; Unaudited Pro Forma Condensed Consolidated Balance Sheet as of December 31, 2023; Unaudited Pro Forma Condensed Consolidated Statement of Operations for the year ended December 31, 2023; and Notes to Unaudited Pro Forma Condensed Consolidated Financial Statements. (d) Exhibits Exhibit No. Description 99.1 Unaudited Pro Forma Condensed Consolidated Financial Information of NovaBay Pharmaceuticals, Inc. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) Cautionary Language Concerning Forward-Looking Statements The pro forma financial information in Exhibit 99.1 contains forward looking statements within the meaning of the " safe harbor " provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of the Company. Accordingly, this Amendment No. 1 contains forward-looking statements that are based upon management ' s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our current product offerings and marketing efforts, the financial impact of the Company ' s recently completed divestiture of DERMAdoctor, our partnerships, and any future revenue that may result from selling our products, as well as generally the Company ' s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NovaBay Pharmaceuticals, Inc. By: /s/ Justin M. Hall Justin M. Hall Chief Executive Officer and General Counsel Dated: May 31, 2024